deswegen gings runter.
seekingalpha.com/article/...dig-its-talons-into-your-portfolio
seekingalpha.com/article/...dig-its-talons-into-your-portfolio
Anzeige
Meldung des Tages: Während die Autobauer zittern, startet in Südkorea die Massenfertigung – und die Aktie wirkt noch günstig
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 4 5 6 7 8 9 10 12
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 4 5 6 7 8 9 10 12
Aufsteiger 2011
Beiträge:
299
Zugriffe: 66.721 / Heute: 1
Zugriffe: 66.721 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +86,26%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +59,98%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +59,11%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +58,90%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +52,91%
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced the appointment of Elizabeth (Bess) Weatherman to the Company's Board of Directors. Ms. Weatherman is a Managing Director of Warburg Pincus and leads the firm's investment activity in the healthcare sector. Warburg Pincus is the majority shareholder of Talon.
The Company also announced the resignation from the Board of Jonathan Leff, formerly a Managing Director at Warburg Pincus. Mr. Leff left Warburg Pincus to join Deerfield Management, Talon's second largest investor.
"We are delighted to welcome Bess to our Board of Directors during this critical stage in the Company's evolution. With more than 20 years investing and advising in the healthcare sector, Bess brings superior strategic insight and extensive industry relationships to the Board. With the accelerated approval of Marqibo®, the Company is now addressing important strategic commercialization choices and Bess will play a key role in guiding the Company's decisions," stated Leon Rosenberg M.D. and Chairman of the Board of Directors of Talon Therapeutics.
Steven Deitcher M.D., President, CEO and Board Member of Talon Therapeutics added, "We also want to thank Jonathan Leff for his excellent service on the Talon Board and wish him well at Deerfield."
"I am pleased to join Talon's Board of Directors," stated Ms. Weatherman. "Marqibo's approved indication addresses an important, underserved hematologic malignancy. I look forward to working closely with Talon's Board and management team."
Ms. Weatherman joined Warburg Pincus in 1988 and leads the firm's investment activities in the healthcare sector, an area in which she helped build the firm's domain expertise. Ms. Weatherman also serves on the board of directors of Bausch & Lomb, Constitution Medical, International Technidyne Corp., JHP Pharmaceuticals, ReSearch Pharmaceutical Services, Silk Road Medical, and Tornier. Ms. Weatherman received a B.A. summa cum laude in English from Mount Holyoke College and holds an M.B.A. from the Stanford Graduate School of Business.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
In addition to Marqibo, Talon has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
Additional information on Talon Therapeutics can be found at www.talontx.com.
The Company also announced the resignation from the Board of Jonathan Leff, formerly a Managing Director at Warburg Pincus. Mr. Leff left Warburg Pincus to join Deerfield Management, Talon's second largest investor.
"We are delighted to welcome Bess to our Board of Directors during this critical stage in the Company's evolution. With more than 20 years investing and advising in the healthcare sector, Bess brings superior strategic insight and extensive industry relationships to the Board. With the accelerated approval of Marqibo®, the Company is now addressing important strategic commercialization choices and Bess will play a key role in guiding the Company's decisions," stated Leon Rosenberg M.D. and Chairman of the Board of Directors of Talon Therapeutics.
Steven Deitcher M.D., President, CEO and Board Member of Talon Therapeutics added, "We also want to thank Jonathan Leff for his excellent service on the Talon Board and wish him well at Deerfield."
"I am pleased to join Talon's Board of Directors," stated Ms. Weatherman. "Marqibo's approved indication addresses an important, underserved hematologic malignancy. I look forward to working closely with Talon's Board and management team."
Ms. Weatherman joined Warburg Pincus in 1988 and leads the firm's investment activities in the healthcare sector, an area in which she helped build the firm's domain expertise. Ms. Weatherman also serves on the board of directors of Bausch & Lomb, Constitution Medical, International Technidyne Corp., JHP Pharmaceuticals, ReSearch Pharmaceutical Services, Silk Road Medical, and Tornier. Ms. Weatherman received a B.A. summa cum laude in English from Mount Holyoke College and holds an M.B.A. from the Stanford Graduate School of Business.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
In addition to Marqibo, Talon has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
Additional information on Talon Therapeutics can be found at www.talontx.com.
ih.advfn.com/...ticchart&s=TLON&p=0&t=19&vol=1
anscheinend deswegen forum-media.finanzen.net/forum/smiley/smiley-cool.gif" style="max-width:560px" alt="" />
ir.talontx.com/releasedetail.cfm?ReleaseID=731771
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced that the Board has authorized a review of strategic alternatives. Goldman Sachs has been engaged to provide financial advisory services. The review of strategic alternatives may lead to a possible transaction, including the merger, business combination, or sale of the company.
No decision has been made to enter into a transaction at this time, and there can be no assurance that Talon will enter into a transaction in the future. The company does not plan to disclose or comment on developments regarding the strategic review process until further disclosure is deemed appropriate.
quelle
siehe #254
dat Lizbeth von Warburg is woll vonne schnelle Truppe.
Könnte ja echt ne turbulente, spannende Zeit vor uns liegen.
Zeit zum aufstocken?
Gruß Wilbär.
Das Geld gleicht dem Seewasser,jemehr man davon trinkt,umso durstiger wird man.
in die gute forum-media.finanzen.net/forum/smiley/smiley-smile.gif" style="max-width:560px" alt="" />
könnten das zum teil insiderkäufe sein?
hoffen wir mal, dass es diesmal wirklich nach oben geht und zwar dauerhaft :-))
keiner mehr billig stücke abgeben forum-media.finanzen.net/forum/smiley/smiley-cool.gif" style="max-width:560px" alt="" />
forum-media.finanzen.net/forum/smiley/smiley-cool.gif" style="max-width:560px" alt="" /> aber ich geb dir recht das auert schon etwas lange
Hier wird sich erst was bewegen, wenn Marqibo auf dem Markt ist.
Laut Website im ersten Quartal.
Laut Website im ersten Quartal.
Talon Therapeutics to Host a Conference Call to Report 2012 Financial Results and Business Update on April 1, 2013
Quelle
ih.advfn.com/p.php?pid=nmona&article=56807378
tritt aber leider nur auf Stelle......könnte jetzt langsam mal losgehen, wir hätten es verdient
:-))))
:-))))
villeicht werden ja einige zittrig wegen montag
was dabei rauskommt
und mit den worten aus iHub "good luck to us all"
Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial Resultsir.talontx.com/releasedetail.cfm?ReleaseID=752606
quelle tlon homepage
berichtigt mich wenn ich falsch liege
aber hab ich das richtig verstanden das das geld noch bis mai reicht?!
hab meine posi vorgestern mal veräusert
will aber weiter unten wieder rein villeicht sehn wir ja noch die 40er
ich kann mir einfach nicht vorstellen das man die fallen lässt
1. marqibo hat die zulassung
2.haben die von Warburg Pincus und Deerfield eine Finanzierung bekommen! die wollten 11 mille bestimmt nich einfach verschenken
villeicht kommt die nächsten tage bzw wochen ne news über ne partnerschaft oder aber auch über ne weitere finanzierung
muß hier halt jeder selbst mit sich ausmachen alles kann nix muß
ne heiße kiste ist das sowiso forum-media.finanzen.net/forum/smiley/smiley-smile.gif" style="max-width:560px" alt="" />
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Talon Therapeutics Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 298 | Aufsteiger 2011 | matflow | wilbär | 18.07.13 10:25 |